MGluR5 Modulation of Behavioral and Epileptic Phenotypes in a Mouse Model of Tuberous Sclerosis Complex

Elyza Kelly, Samantha M. Schaeffer, Sameer C. Dhamne, Jonathan O. Lipton, Lothar Lindemann, Michael Honer, Georg Jaeschke, Chloe E. Super, Stephen Ht Lammers, Meera E. Modi, Jill L Silverman, John R. Dreier, David J. Kwiatkowski, Alexander Rotenberg, Mustafa Sahin

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Drugs targeting metabotropic glutamate receptor 5 (mGluR5) have therapeutic potential in autism spectrum disorders (ASD), including tuberous sclerosis complex (TSC). The question whether inhibition or potentiation of mGluR5 could be beneficial depends, among other factors, on the specific indication. To facilitate the development of mGluR5 treatment strategies, we tested the therapeutic utility of mGluR5 negative and positive allosteric modulators (an mGluR5 NAM and PAM) for TSC, using a mutant mouse model with neuronal loss of Tsc2 that demonstrates disease-related phenotypes, including behavioral symptoms of ASD and epilepsy. This model uniquely enables the in vivo characterization and rescue of the electrographic seizures associated with TSC. We demonstrate that inhibition of mGluR5 corrects hyperactivity, seizures, and elevated de novo synaptic protein synthesis. Conversely, positive allosteric modulation of mGluR5 results in the exacerbation of hyperactivity and epileptic phenotypes. The data suggest a meaningful therapeutic potential for mGluR5 NAMs in TSC, which warrants clinical exploration and the continued development of mGluR5 therapies.

Original languageEnglish (US)
Pages (from-to)1457-1465
Number of pages9
JournalNeuropsychopharmacology
Volume43
Issue number6
DOIs
StatePublished - May 1 2018

Fingerprint

Metabotropic Glutamate 5 Receptor
Tuberous Sclerosis
Phenotype
Seizures
Therapeutics
Behavioral Symptoms
Drug Delivery Systems
Epilepsy

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health

Cite this

Kelly, E., Schaeffer, S. M., Dhamne, S. C., Lipton, J. O., Lindemann, L., Honer, M., ... Sahin, M. (2018). MGluR5 Modulation of Behavioral and Epileptic Phenotypes in a Mouse Model of Tuberous Sclerosis Complex. Neuropsychopharmacology, 43(6), 1457-1465. https://doi.org/10.1038/npp.2017.295

MGluR5 Modulation of Behavioral and Epileptic Phenotypes in a Mouse Model of Tuberous Sclerosis Complex. / Kelly, Elyza; Schaeffer, Samantha M.; Dhamne, Sameer C.; Lipton, Jonathan O.; Lindemann, Lothar; Honer, Michael; Jaeschke, Georg; Super, Chloe E.; Lammers, Stephen Ht; Modi, Meera E.; Silverman, Jill L; Dreier, John R.; Kwiatkowski, David J.; Rotenberg, Alexander; Sahin, Mustafa.

In: Neuropsychopharmacology, Vol. 43, No. 6, 01.05.2018, p. 1457-1465.

Research output: Contribution to journalArticle

Kelly, E, Schaeffer, SM, Dhamne, SC, Lipton, JO, Lindemann, L, Honer, M, Jaeschke, G, Super, CE, Lammers, SH, Modi, ME, Silverman, JL, Dreier, JR, Kwiatkowski, DJ, Rotenberg, A & Sahin, M 2018, 'MGluR5 Modulation of Behavioral and Epileptic Phenotypes in a Mouse Model of Tuberous Sclerosis Complex', Neuropsychopharmacology, vol. 43, no. 6, pp. 1457-1465. https://doi.org/10.1038/npp.2017.295
Kelly, Elyza ; Schaeffer, Samantha M. ; Dhamne, Sameer C. ; Lipton, Jonathan O. ; Lindemann, Lothar ; Honer, Michael ; Jaeschke, Georg ; Super, Chloe E. ; Lammers, Stephen Ht ; Modi, Meera E. ; Silverman, Jill L ; Dreier, John R. ; Kwiatkowski, David J. ; Rotenberg, Alexander ; Sahin, Mustafa. / MGluR5 Modulation of Behavioral and Epileptic Phenotypes in a Mouse Model of Tuberous Sclerosis Complex. In: Neuropsychopharmacology. 2018 ; Vol. 43, No. 6. pp. 1457-1465.
@article{0209f67b22334be9a4c88c18d9b050a4,
title = "MGluR5 Modulation of Behavioral and Epileptic Phenotypes in a Mouse Model of Tuberous Sclerosis Complex",
abstract = "Drugs targeting metabotropic glutamate receptor 5 (mGluR5) have therapeutic potential in autism spectrum disorders (ASD), including tuberous sclerosis complex (TSC). The question whether inhibition or potentiation of mGluR5 could be beneficial depends, among other factors, on the specific indication. To facilitate the development of mGluR5 treatment strategies, we tested the therapeutic utility of mGluR5 negative and positive allosteric modulators (an mGluR5 NAM and PAM) for TSC, using a mutant mouse model with neuronal loss of Tsc2 that demonstrates disease-related phenotypes, including behavioral symptoms of ASD and epilepsy. This model uniquely enables the in vivo characterization and rescue of the electrographic seizures associated with TSC. We demonstrate that inhibition of mGluR5 corrects hyperactivity, seizures, and elevated de novo synaptic protein synthesis. Conversely, positive allosteric modulation of mGluR5 results in the exacerbation of hyperactivity and epileptic phenotypes. The data suggest a meaningful therapeutic potential for mGluR5 NAMs in TSC, which warrants clinical exploration and the continued development of mGluR5 therapies.",
author = "Elyza Kelly and Schaeffer, {Samantha M.} and Dhamne, {Sameer C.} and Lipton, {Jonathan O.} and Lothar Lindemann and Michael Honer and Georg Jaeschke and Super, {Chloe E.} and Lammers, {Stephen Ht} and Modi, {Meera E.} and Silverman, {Jill L} and Dreier, {John R.} and Kwiatkowski, {David J.} and Alexander Rotenberg and Mustafa Sahin",
year = "2018",
month = "5",
day = "1",
doi = "10.1038/npp.2017.295",
language = "English (US)",
volume = "43",
pages = "1457--1465",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - MGluR5 Modulation of Behavioral and Epileptic Phenotypes in a Mouse Model of Tuberous Sclerosis Complex

AU - Kelly, Elyza

AU - Schaeffer, Samantha M.

AU - Dhamne, Sameer C.

AU - Lipton, Jonathan O.

AU - Lindemann, Lothar

AU - Honer, Michael

AU - Jaeschke, Georg

AU - Super, Chloe E.

AU - Lammers, Stephen Ht

AU - Modi, Meera E.

AU - Silverman, Jill L

AU - Dreier, John R.

AU - Kwiatkowski, David J.

AU - Rotenberg, Alexander

AU - Sahin, Mustafa

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Drugs targeting metabotropic glutamate receptor 5 (mGluR5) have therapeutic potential in autism spectrum disorders (ASD), including tuberous sclerosis complex (TSC). The question whether inhibition or potentiation of mGluR5 could be beneficial depends, among other factors, on the specific indication. To facilitate the development of mGluR5 treatment strategies, we tested the therapeutic utility of mGluR5 negative and positive allosteric modulators (an mGluR5 NAM and PAM) for TSC, using a mutant mouse model with neuronal loss of Tsc2 that demonstrates disease-related phenotypes, including behavioral symptoms of ASD and epilepsy. This model uniquely enables the in vivo characterization and rescue of the electrographic seizures associated with TSC. We demonstrate that inhibition of mGluR5 corrects hyperactivity, seizures, and elevated de novo synaptic protein synthesis. Conversely, positive allosteric modulation of mGluR5 results in the exacerbation of hyperactivity and epileptic phenotypes. The data suggest a meaningful therapeutic potential for mGluR5 NAMs in TSC, which warrants clinical exploration and the continued development of mGluR5 therapies.

AB - Drugs targeting metabotropic glutamate receptor 5 (mGluR5) have therapeutic potential in autism spectrum disorders (ASD), including tuberous sclerosis complex (TSC). The question whether inhibition or potentiation of mGluR5 could be beneficial depends, among other factors, on the specific indication. To facilitate the development of mGluR5 treatment strategies, we tested the therapeutic utility of mGluR5 negative and positive allosteric modulators (an mGluR5 NAM and PAM) for TSC, using a mutant mouse model with neuronal loss of Tsc2 that demonstrates disease-related phenotypes, including behavioral symptoms of ASD and epilepsy. This model uniquely enables the in vivo characterization and rescue of the electrographic seizures associated with TSC. We demonstrate that inhibition of mGluR5 corrects hyperactivity, seizures, and elevated de novo synaptic protein synthesis. Conversely, positive allosteric modulation of mGluR5 results in the exacerbation of hyperactivity and epileptic phenotypes. The data suggest a meaningful therapeutic potential for mGluR5 NAMs in TSC, which warrants clinical exploration and the continued development of mGluR5 therapies.

UR - http://www.scopus.com/inward/record.url?scp=85045620934&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045620934&partnerID=8YFLogxK

U2 - 10.1038/npp.2017.295

DO - 10.1038/npp.2017.295

M3 - Article

VL - 43

SP - 1457

EP - 1465

JO - Neuropsychopharmacology

JF - Neuropsychopharmacology

SN - 0893-133X

IS - 6

ER -